AXSM Axsome Therapeutics
- 74.800
- +0.610+0.82%
- 75.990
- +1.190+1.59%
Axsome Therapeutics News
Damo: The Axsome Therapeutics (AXSM.US) rating was raised from a wait-and-see shareholding rating to an increase rating, and the target price was adjusted from $90.00 to $115.00.
Axsome Therapeutics Analyst Ratings
Buy Rating Affirmed for Axsome Therapeutics on Robust Product Pipeline and Market Growth Potential
Buy Rating Affirmed for Axsome Therapeutics Amidst Anticipated Clinical Data and Resilient Product Performance
Neurocrine Biosciences Upgraded at Wells Fargo on Pipeline
Auvelity's Strong Performance Sustains Buy Rating for Axsome Therapeutics
Cantor Fitzgerald Inc.: The Axsome Therapeutics (AXSM.US) rating was reaffirmed and adjusted from an increase holdings to an increase rating, with a target price of $107.00.
Axsome Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Axsome Therapeutics (AXSM) and Premier (PINC)
Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Exelixis (EXEL) and Axsome Therapeutics (AXSM)
Axsome Therapeutics Analyst Ratings
Buy Rating Affirmed for Axsome Therapeutics Amid Strong Clinical Pipeline and Market Expansion Potential
Axsome Therapeutics Analyst Ratings
Mizuho Securities Ups Price Target on Axsome Therapeutics to $109 From $108, Keeps Buy Rating
Analysts Offer Insights on Healthcare Companies: Regulus (RGLS), Axsome Therapeutics (AXSM) and Olink Holding (OLK)
Citigroup Adjusts Price Target on Axsome Therapeutics to $127 From $125, Maintains Buy Rating
RBC Lifts Price Target on Axsome Therapeutics to $128 From $123, Says AXS-12 Reaching Primary Endpoint 'Should Enable Approval,' Keeps Outperform Rating
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Axsome Therapeutics (AXSM) and Sotera Health (SHC)
Buy Rating Affirmed for Axsome Therapeutics With Increased Target Price Following Strong AXS-12 Trial Results
Axsome Therapeutics Analyst Ratings
Analysis
Price Target
No Data
